Our Medicinal Chemistry Department has extensive expertise and successful track records in early stage drug discovery including hit identification, hit to lead optimization, computer-aided drug design, lead selection and optimization, as well as ADME/Tox profile improvement for the discovery of small-molecule drugs.  This enables our clients to develop effective, patentable, and safe drugs.

Teams at Granlen utilize both combinatorial and traditional approaches to optimize lead compounds for structure-activity relationships (SAR) studies by leveraging our vast medicinal chemistry knowledge. Further, our teams can design and synthesize advanced leads to optimize potency, selectivity and specificity, and to improve ADME-Tox profiles and deliverability to provide your preclinical candidate.

Granlen’s experienced computational group can provide Structure/Ligand-based drug design with cutting edge technologies, such as, HTS data analysis, scaffold-based compound classification, and 2D or 3D-based virtual screening.